Featured Research

from universities, journals, and other organizations

Controlling Bone Disease Improves Survival Of Hemodialysis Patients

Date:
July 3, 2008
Source:
American Society of Nephrology
Summary:
Consistently maintaining certain blood levels of markers of bone metabolism and disease can prolong the lives of patients on hemodialysis, according to a new study. The findings indicate that keeping parathyroid hormone, calcium, and phosphorus levels in control is critically important for dialysis patients with chronic kidney disease.

Consistently maintaining certain blood levels of markers of bone metabolism and disease can prolong the lives of patients on hemodialysis, according to a new study. The findings indicate that keeping parathyroid hormone, calcium, and phosphorus levels in control is critically important for dialysis patients with chronic kidney disease (CKD).

Because mineral and bone disorder affects most patients with CKD, the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI) has set specific treatment targets for the indicators of this disorder--serum levels of parathyroid hormone, calcium, and phosphorus. While research has shown that elevations in these markers are associated with increased morbidity and mortality in dialysis patients, no study has investigated the long-term control of these parameters.

Dr. Mark Danese of Outcomes Insights, Inc. (Newbury Park, CA), and his colleagues, Dr. Vasily Belozeroff and Dr. Karen Smirnakis of Amgen, Inc. (Thousand Oaks, CA) and Dr. Kenneth Rothman of Research Triangle Institute (Research Triangle Park, NC), set out to determine whether more consistent control of parathyroid, calcium, and phosphorus levels within the KDOQI target ranges is associated with improved survival. The study was conducted among 24,803 adults initiating dialysis between 2000 and 2002. The researchers assessed whether survival was improved when patients were within the three target levels simultaneously. They also examined whether survival was improved when patients were within each of the three target levels for prolonged periods of time.

The researchers reported that it was important to meet as many of the targets as possible at any given time. Meeting the target for none of the three markers was associated with a 51% higher risk of death compared with patients who achieved targets simultaneously for all three markers. Patients meeting only one target had a 35% to 39% increased risk of death, and patients meeting any two targets had a 15% to 21% higher risk of death.

Dr. Danese and his team also found that the longer an individual met one or more targets, the better. For each marker, patients who achieved target values for less than three months had the highest risk of death compared with those who did so for one year. Compared with patients whose individual target levels were maintained for one year, patients with a parathyroid in target for less than three months had a 34% higher risk of death, patients with calcium in target for less than three months had a 16% higher risk of death, and patients with phosphorus in target for less than three months had a 62% higher risk of death.

The study also revealed that prior to the introduction of the KDOQI guidelines, relatively few patients either simultaneously met the targets for parathyroid hormone, calcium, and phosphorus or met any target for a full year. The authors discovered that levels of these parameters outside the KDOQI target ranges may account for as much as 20% of deaths in dialysis patients.

"These results suggest that there is a need for more consistent achievement of the KDOQI mineral metabolism targets, and that meeting this need may result in improved survival for incident hemodialysis patients," the authors write. They note that this can be a challenge, however, because the use of current treatment options often requires a tradeoff between controlling parathyroid hormone and controlling calcium and phosphorus.

This study was funded by Amgen, Inc. Drs. Belozeroff and Smirnakis are employed by Amgen, Inc. Drs. Danese and Rothman are consultants to Amgen, Inc.


Story Source:

The above story is based on materials provided by American Society of Nephrology. Note: Materials may be edited for content and length.


Journal Reference:

  1. Consistent Control of Mineral and Bone Disorder in Incident Hemodialysis Patients. Clinical Journal of the American Society Nephrology, September Print Issue, Online July 2, 2008

Cite This Page:

American Society of Nephrology. "Controlling Bone Disease Improves Survival Of Hemodialysis Patients." ScienceDaily. ScienceDaily, 3 July 2008. <www.sciencedaily.com/releases/2008/07/080702121145.htm>.
American Society of Nephrology. (2008, July 3). Controlling Bone Disease Improves Survival Of Hemodialysis Patients. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2008/07/080702121145.htm
American Society of Nephrology. "Controlling Bone Disease Improves Survival Of Hemodialysis Patients." ScienceDaily. www.sciencedaily.com/releases/2008/07/080702121145.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins